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Ethyl 3,4-di-O-benzyl-6-O-fluorenylmethoxycarbonyl-2-O-levulinoyl-1thio-α-D-mannopyranoside (2)
A suspension of N,N'-dicyclohexylcarbodiimide (DCC, 0.19 g, 0.94 mmol) and 4dimethylaminopyridine (DMAP, 0.01 g, 0.09 mmol) in anhydrous DCM (3 mL) was added to a solution of S2 (0.19 g, 0.30 mmol) and levulinic acid (0.07 ml, 0.69 mmol)
in DCM (5 mL) at 0 °C. The clear solution was stirred at room temperature and monitored by TLC for 1.5 h. The mixture was filtered over celite and the filtrate concentrated under vacuum. The product was purified by column chromatography (20% ethyl acetate/hexane) to give 2 as a sticky white solid (0.2 g, 91%). Rf 0.40 (EtOAc/hexane, 1:4, v/v) . IR (film) νmax: 3033, 2930, 1745, 1721, 1498, 1453, 1368, 1256, 1156, 1100, 1031, 969, 851, 788, 759, 742 , 700 cm −1 ; 1 H NMR (400 MHz, CDCl3) 206.39, 171.99, 155.17, 143.55, 143.38, 141.41, 141.39, 138.09, 137.65, 128.55, 128.33, 128.15, 128.00, 127.95, 127.27, 127.25, 125.27, 125.22, 120.17, 82.47, 78.55, 75.33, 74.32, 71.79, 70.52, 70.17, 70.00, 66.92, 46.87, 38.06, 29.88, 28.29, 25.68 ppm; HRMS (m/z): [M + Na] + calcd for C42H44O9SNa, 747.2598; found, 747.2532.
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Building block 1, 3, and photolabile resin S0 were prepared according to reported procedures [2] [3] [4] [5] .
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3. Pre-automation steps 3.1 
. Materials and measurements
Solvents used for dissolving all building blocks and making AGA solutions were taken from an anhydrous solvent system (jcmeyer phoenix solvent drying system). Solvents for washing were HPLC grade. The building blocks were coevaporated three times with anhydrous toluene and dried for 1 h under high vacuum prior to use. All solution bottles were freshly prepared and kept under argon during the automation process.
Isolated yields of products were calculated on the basis of resin loading. Resin loading was determined following a reported protocol [1] . Briefly, functionalized resin (40 mg) was treated with one glycosylation cycle using 65 mg of BB A (excess), followed by DBU-promoted Fmoc cleavage and determination of dibenzofulvene concentration by UV absorbance. All automated syntheses were performed on a 0.0125 mmol scale.
Resin was placed in the reaction vessel and was swollen in DCM for 20 min at room temperature before starting the first module. During this time, all reagent lines involved in the synthesis were washed and primed. 
Modules for automated synthesis Module A: Preparation of resin for synthesis
All automated syntheses were performed on 0.0125 mmol scale. Resin was placed in the reaction vessel and swollen in DCM for 20 min at room temperature prior to synthesis. Before the first glycosylation, the resin was washed with the DMF, THF, and DCM (three times with 2 mL for 25 s each).
Module B: Acidic wash
The resin was swollen in 2 mL DCM and 1 mL of solution B (TMSOTf) was delivered to the reaction vessel. After 3 min at −20 °C, the solution was drained and the resin was washed with 2 mL DCM for 25 s.
Module C1: Glycosylation
The thioglycoside building block solution (6.5 equiv, 0.08 mmol in 1.0 mL DCM) was delivered to the reaction vessel and the temperature was adjusted to −20 °C. After the set temperature was reached, the reaction was started by the addition of the activator solution C. The glycosylation was performed for 5 min at −20 °C and for 20 min at 0 °C. After the glycosylation, the solution was drained and the resin was washed with DCM, DCM:dioxane (1:2, v/v, 3 mL for 20 s) and DCM (2 × 2 mL for 25 s). 
Action
Module C2: Glycosylation
The thioglycoside building block solution (6.5 equiv, 0.08 mmol in 1.0 mL DCM) was delivered to the reaction vessel and the temperature was adjusted to −40 °C. After the set temperature was reached, the reaction was started by the addition of the activator solution C. The glycosylation was performed for 5 min at −40 °C and for 30 min at −20 °C. After the glycosylation, the solution was drained and the resin was washed with DCM, DCM:dioxane (1:2, v/v, 3 mL for 20 s) and DCM (two times, each with 2 mL for 25 s).
Module D: Fmoc deprotection
The resin was washed with DMF (three times with 2 mL for 25 s) and the temperature of the reaction vessel was adjusted to 25 °C. Fmoc deprotection solution (2 mL) was delivered into the reaction vessel. After 5 min, the reaction solution was drained and the resin washed with DMF (three times with 3 mL for 25 s) and DCM (five times each with 2 mL for 25 s).
Module E: Lev deprotection
The resin was washed with DMF (3 × 30 min) and 1.3 mL DCM was added to the reaction vessel. Solution E (0.8 mL) was added to the reaction vessel, and the temperature was adjusted to 25 °C. After 30 min, the reaction solution was drained and the whole cycle was repeated two more times. After Lev deprotection was complete, the resin was washed with DMF, THF, and DCM.
Module F: Capping
The resin was washed with DMF (two times with 2 mL for 25 s) and the temperature was adjusted to 25 °C. 2 mL of solution G was delivered into the reaction vessel. After 1 min, the reaction solution was drained and the resin was washed with DCM (three times with 3 mL for 25 s). 4 mL of capping solution F was delivered into the reaction vessel. After 20 min, the reaction solution was drained and the resin washed with DCM (three times with 3 mL for 25 s) [6] .
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Post-synthesizer manipulations
Cleavage from the solid support: The oligosaccharides were cleaved from the solid support using the Vapourtec E-Series UV-150 photoreactor as reported previously [7] .
Purification: The crude products were analyzed and purified using analytical and preparative HPLC (Agilent 1200 Series spectrometer).
 Cleavage from the solid support, as described in Post-synthesizer manipulations, followed by purification using preparative HPLC (Method B) afforded the fully protected hexasaccharide 4 (20 mg, 55%).
Crude NP-HPLC of hexasaccharide 4 (ELSD trace, Method A, tR = 25.3 min). 1  165. 97, 165.73, 165.65, 165.54, 156.51, 138.63, 138.58, 138.41, 138.37, 138.04, 137.74, 137.67, 137.65, 137.62, 136.78, 133.45, 133.41, 130.08, 130.03, 129.99, 128.77, 128.70, 128.62, 128.47, 128.43, 128.34, 128.29, 128.26, 128.18, 128.14, 127.82, 127.78, 127.75, 127.53, 127.48, 127.44, 127.34, 127.24, 127.22, 98.58, 98.51, 98.25, 97.99, 78.72, 78.42, 78.37, 78.34, 78.28, 77.79, 76.84, 75.31, 75.22, 75.16, 75.12, 74.30, 74.01, 73.91, 73.85, 73.79, 72.20, 71.76, 71.53, 71.43, 71.30, 71.09, 71.01, 70.84, 69.16, 68.65, 68.52, 68.46, 67.89, 66.68, 66.20, 65.91, 65.82, 65.54, 61.93, 41.07, 29.90, 29.16, 23 .55 ppm; HRMS (m/z): [M + Na] + calcd for C175H175NO39Na, 2937.163; found, 2937.160. Proton and carbon NMR signals are in agreement with previous reports by Delbianco and co-workers [5] .
Deprotection of 4 (as described in Modules G and H), followed by purification using preparative HPLC (Method E, tR = 22.2 min) afforded compound 10 (3.9 mg, 52%). S13 RP-HPLC of purified hexasaccharide 10 (ELSD trace, Method C, tR = 22.2 min).
Analytical data for 10. 1 89, 99.42, 99.30, 72.72, 70.92, 70.84, 70.80, 70.78, 70.72, 70.69, 70.55, 70.07, 69.98, 69.94, 67.63, 66.75, 66.61, 66.57, 65.61, 65.58, 65.53, 60.94, 39.38, 28.04, 26.57, 22.54 165.52, 165.43, 165.38, 156.51, 138.66, 138.53, 138.49, 138.29, 138.21, 138.10, 138.04, 137.90, 137.81, 137.66, 137.14, 136.79, 136.76, 133.52, 133.43, 133.27, 133.22, 130.27, 130.05, 129.99, 129.90, 129.78, 129.34, 128.63, 128.55, 128.43, 128.35, 128.28, 128.16, 128.14, 128.02, 127.97, 127.88, 127.81, 127.77, 127.71, 127.56, 127.47, 127.34, 100.24, 99.88, 99.28, 98.87, 97.64, 97.55, 79.24, 79.11, 78.97, 78.61, 78.50, 75.33, 75.21, 75.12, 74.93, 74.59, 74.42, 74.10, 73.99, 73.40, 72.78, 72.49, 71.91, 71.81, 71.75, 71.39, 71.24, 71.06, 70.49, 69.62, 69.57, 69.23, S16 68.81, 67.84, 66.69, 66.02, 65.87, 62.59, 62.27, 61.93, 41.05, 29.86, 29.14, 23 23 , 99., 99., 98., 78.72, 73.24, 73.17, 72.73, 71.17, 71.08, 70.83, 70.57, 70.38, 69.93, 67.55, 66.64, 66.61, 66.59, 66.50, 66.42, 65.78, 65.58, 65.11, 60.99, 60.96, 60.86, 39.29, 27.95, 26.49, 22.42 99, 165.75, 165.73, 165.67, 165.53, 165.44, 165.39, 165.31, 156.52, 138.75, 138.61, 138.57, 138.49, 138.39, 138.31, 138.25, 138.08, 138.00, 137.91, 137.79, 137.73, 137.69, 137.63, 137.57, 136.82, 133.44, 133.21, 130.14, 130.06, 130.00, 129.90, 129.81, 128.78, 128.71, 128.62, 128.61, 128.47, 128.40, 128.31, 128.17, 128.11, 127.88, 127.81, 127.77, 127.56, 127.50, 127.38, 127.26, 127.11, 100.32, 99.57, 99.33, 99.04, 98.70, 98.65, 98.55, 98.43, 98.27, 98.01, 97.70, 78.73, 78.44, 78.37, 78.31, 78.24, 75.32, 75.19, 75.12, 74.34, 74.05, 73.95, 73.90, 73.59, 71.96, 71.86, 71.78, 71.68, 71.55, 71.47, S24 5.4. α(1-6) α (1) (2) (3) (4) (5) Linear octaarabinomannoside (7) Cleavage from the solid support, as described in Post-synthesizer manipulation, followed by purification using a preparative HPLC (Method B) to provide the fully protected linear octasaccharide 7. For procedure A: 4 mg, 1.10 μmol, 9%, based on resin loading. For procedure B: 25 mg, 6.8 μmol, 56%, based on resin loading. S29 5.5. α(1-6) α(1-5) linear dodecaarabinomannoside (8) 
